{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:59:09Z","timestamp":1787014749278,"version":"build-2736575974"},"reference-count":40,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2011,8,8]],"date-time":"2011-08-08T00:00:00Z","timestamp":1312761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background\u2002<\/jats:bold>\n                    Epidermolysis bullosa acquisita (EBA) is a chronic subepidermal blistering disease that is caused by antibodies binding to type VII collagen within anchoring fibrils. It is rare disease with an incidence of 0.25 cases per 1\u2003000\u2003000 population.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective\u2002<\/jats:bold>\n                    The objective of this study is to report the treatment outcomes with intravenous immunoglobulin (IVIg) therapy in 10 patients with severe and widespread EBA non\u2010responsive to conventional therapy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods\u2002<\/jats:bold>\n                    Patients were treated according to a protocol published in a Consensus Statement to treat autoimmune mucocutaneous blistering diseases, including EBA with IVIg. A dose of 2\u2003g\/kg\/cycle was used.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2002<\/jats:bold>\n                    Ten patients: four males and six females, all were North American Caucasian. The age at onset varied from 37 to 75\u2003years (mean 57.4). A satisfactory clinical response was observed in all 10 patients. The patients received 16\u201331 cycles (mean 23.1) of IVIg over a period of 30\u201352\u2003months (mean 38.8). Once IVIg was initiated, earlier drugs (prednisone, dapsone and others) were gradually withdrawn over a 5\u20139\u2003month period (mean 7.2). Thereafter, IVIg was used as monotherapy. No serious side\u2010effects were observed. The follow\u2010up period since discontinuation of IVIg varied from 29 to 123\u2003months (mean 53.9). During this follow\u2010up period, recurrence of disease was not observed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion\u2002<\/jats:bold>\n                    The data suggest that IVIg can produce a long\u2010term sustained clinical remission in patients with EBA. In the patients, of this study concomitant therapy could be discontinued and IVIg was used as monotherapy.\n                  <\/jats:p>","DOI":"10.1111\/j.1468-3083.2011.04205.x","type":"journal-article","created":{"date-parts":[[2011,8,8]],"date-time":"2011-08-08T03:36:32Z","timestamp":1312774592000},"page":"1074-1083","source":"Crossref","is-referenced-by-count":31,"title":["Treatment of epidermolysis bullosa acquisita with intravenous immunoglobulin in patients non\u2010responsive to conventional therapy: clinical outcome and post\u2010treatment long\u2010term follow\u2010up"],"prefix":"10.1111","volume":"26","author":[{"given":"A.R.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.M.","family":"G\u00fcrcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,8,8]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1159\/000131455"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.05933.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1995.01690130050009"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12285634"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.03886.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.113693"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0738-081X(00)00189-9"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.8.1051"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.116339"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.116337"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.116338"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.11.012"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70189-Z"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(09)80064-9"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb00735.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)80411-2"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.2576m.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02817.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03368.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2002.00386.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.113682"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2005.01989.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.11.1615"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.06.029"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.08.003"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03439.x"},{"key":"e_1_2_6_28_2","first-page":"50","article-title":"Epidermolysis bullosa acquisita in an 18\u2010year\u2010old African\u2010American male: a case report","volume":"62","author":"Howard T","year":"2009","journal-title":"S D Med"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2005.tb00727.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.020"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2001.00174-2.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02245.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.2.147"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.2.192"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1997.tb03725.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630600964999"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1006\/clim.2001.5113"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.5771549.x"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(86)70103-5"},{"key":"e_1_2_6_40_2","first-page":"CD004056","article-title":"Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita","author":"Kirtschig G","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2009.00799.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2011.04205.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2011.04205.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T18:24:59Z","timestamp":1697307899000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2011.04205.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,8]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1111\/j.1468-3083.2011.04205.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04205.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,8]]}}}